Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 861-872

  Piana, Chiara ^a   Zhao, Wei ^b,c   Adkison, Kimberly ^d   Burger, David ^e   Jacqz Aigrain, Evelyne ^b,c   Danhof, Meindert ^a   Della Pasqua, Oscar ^a,f  

^a LEIDEN UNIVERSITY   (Netherlands)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c INSERM   (France)

^d GLAXOSMITHKLINE   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

dose rationale; drug development; lamivudine; paediatrics; population pharmacokinetics

Indexed keywords

LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CLINICAL STUDY; COMPARTMENT MODEL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXPOSURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION; BIOLOGICAL MODEL; HIV INFECTIONS; PRESCHOOL CHILD;

ANTI-HIV AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MALE; MODELS, BIOLOGICAL;

EID: 84899079507     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12247     Document Type: Article

References (36)

1. World Health Organization. WHO Recommendations on the Diagnosis of HIV Infection in Infants and Children. Geneva: World Health Organization, available at 2010. http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html (last acessed 4 May 2013).
2. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE,. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41-66.
3. Kumar PN, Patel P,. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol 2010; 6: 105-114.
4. Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, Rubin M, Yuen G, Mueller B, Sloas M, Wood L, Balis F, Shearer GM, Brouwers P, Goldsmith J, Pizzo PA,. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. TheNational Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996; 174: 16-25.
5. Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK, Hussey EK,. Pharmacokinetics of lamivudine administered alone and with trimethoprim- sulfamethoxazole. Clin Pharmacol Ther 1996; 59: 550-558.
6. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK,. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995; 35: 1174-1180.
7. Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A,. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999; 13: 2239-2250.
8. Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M, Pediatric AIDS Clinical Trials Group. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother 2007; 51: 4297-4302.
9. Burger DM, Verweel G, Rakhmanina N, Wissen CPWGM V-V, La Porte CJL, Bergshoeff AS, Lyall H, Hartwig NG, Green H, Soldin S, Gibb DM, de Groot R,. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007; 81: 517-520.
10. Bouazza N, Hirt D, Blanche S, Frange P, Rey E, Tréluyer JM, Tréluyer JM, Urien S,. Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. Antimicrob Agents Chemother 2011; 55: 3498-3504.
11. Zhang C, Denti P, van der Walt J-S, Ren Y, Smith P, Karlsson MO,. Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring. Ther Drug Monit 2012; 34: 481-484.
12. Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O,. A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther 2010; 87: 294-302.
13. Mandema JW, Verotta D, Sheiner LB,. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511-528.
14. Anderson BJ, Allegaert K, Holford NHG,. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006; 165: 819-829.
15. Anderson BJ, Allegaert K, Holford NHG,. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165: 741-746.
16. Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, Le Prevost M,. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10: 239-246.
17. Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir Ther 2010; 15: 297-305.
18. Musiime V, Kendall L, Bakeera-Kitaka S, Snowden WB, Odongo F, Thomason M,. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther 2010; 15: 1115-1124.
19. Verweij-van Wissen CPWGM, Aarnoutse RE, Burger DM,. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816: 121-129.
20. Beal SL, Sheiner LB,. NONMEM User's Guide. San Francisco, CA: NONMEM Project Group, University of California, 2011.
21. Duffull SB, Kirkpatrick CMJ, Green B, Holford NHG,. Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat 2005; 15: 53-73.
22. Brendel K, Comets E, Laffont C, Laveille C, Mentré F,. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006; 23: 2036-2049.
23. Lindbom L, Ribbing J, Jonsson EN,. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85-94.
24. Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H,. Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children. Antimicrob Agents Chemother 2010; 54: 3280-3286.
25. Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S,. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther 2012; 91: 272-280.
26. Mager H,. Covariate selection in population pharmacokinetics/ pharmacodynamics. Int J Clin Pharmacol Ther 2004; 42: 187-188.
27. Ribbing J, Jonsson EN,. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 2004; 31: 109-134.
28. Linezolid. 2012. Summary of product characteristics. http://www.mhra.gov. uk/home/groups/spcpil/documents/spcpil/con1369199040944.pdf (last accessed on 01 Aug 2013).
29. Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, Mudd PN Jr, Pakes GE,. Pharmacokinetics of zidovudine and lamivudine in neonates following co-administration of oral doses every 12 hours. J Clin Pharmacol 2001; 41: 732-741.
30. Mirochnick M, Best BM,. Antiretroviral pharmacology in pregnant women and newborns. In: Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice, eds, Yaffe SJ, Aranda JV,. Baltimore, MD: Lippincott Williams & Wilkins, 2010; 272.
31. Zuppa AF, Nicolson SC, Barrett JS, Gastonguay MR,. Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. J Pediatr 2011; 159: 414-419.
32. Guilhaumou R, Simon N, Quaranta S, Verschuur A, Lacarelle B, Andre N,. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother Pharmacol 2011; 68: 1191-1198.
33. Bressolle F, Khier S, Rochette A, Kinowski JM, Dadure C, Capdevila X,. Population pharmacokinetics of nalbuphine after surgery in children. Br J Anaesth 2011; 106: 558-565.
34. Bouillon-Pichault M, Nabbout R, Chhun S, Rey E, Chiron C, Dulac O,. Topiramate pharmacokinetics in infants and young children: contribution of population analysis. Epilepsy Res 2011; 93: 208-211.
35. Cella M, Knibbe C, Danhof M, Della Pasqua O,. What is the right dose for children. Br J Clin Pharmacol 2010; 70: 597-603.
36. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR,. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000; 14: 2137-2144.